A statement for extensive primary cytoreductive surgery in advanced ovarian cancer

BJOG. 2009 May;116(6):865; author reply 865-6. doi: 10.1111/j.1471-0528.2009.02130.x.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Chemotherapy, Adjuvant
  • Female
  • Humans
  • Neoadjuvant Therapy
  • Ovarian Neoplasms / therapy*

Substances

  • Antineoplastic Agents